Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Slides:

Advertisements

Similar presentations

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Advertisements

Summary of TB cases across indications and trial periods

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.

Main fields of interest.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

Patient disposition through 48 weeks in RA-BEYOND

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

Frequency of patients in flare at each time point over 3 months

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Spectrum of ultrasound grey scale on the dorsal aspects of the wrists ((a) to (d)), MCPs ((e) to (h)), PIPs ((i) to (l)) and MTPs ((m) to (p)): grade 0.

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.

Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 3 years of disease (B). Fatigue severity across.

Column bar graphs showing Health Assessment Questionnaire (HAQ) scores and pain score on Visual Analogue Scale (VAS) (scale 0–10) that were collected at.

Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group

EULAR-defined characteristics describing arthralgia at risk for RA

SF-36 domain scores at baseline and 24 weeks compared with age-matched and gender-matched normative values in the (A) AMBITION and (B) ADACTA trial populations.

Low-dose glucocorticoid chronotherapy in rheumatoid arthritis (RA) include the night-time-release prednisone, a timing drug release formulation with administration.

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Examples of MRI at presentation with clinically suspect arthralgia (CSA) (top panel) and at IA development (bottom panel), showing joints (A) from no inflammation.

Kaplan-Meier One Minus Survival plot showing cumulative progression to clinical arthritis for patients with clinically suspect arthralgia divided in four.

Percentage of patients with RA achieving DAS28(CRP)<2

JSN and SvdH damage and progression scores with and without the CMC3-5 joints. JSN and SvdH damage and progression scores with and without the CMC3-5 joints.

Joint damage progression evaluated as a comparison between abatacept plus MTX (grey bar) and placebo plus MTX groups (open bar). Joint damage progression.

JSN incidence of individual joints (left axis) and percentage of individual joints relative to the total number of joints affected by JSN (right axis)

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

SRMs at 3 and 6 months for the final ultrasound inflammation score (USRA9) bilaterally and previously proposed scores (A) GSUS in the early RA cohort,

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Distribution of swelling and tenderness in joints with or without x-ray progression. Distribution of swelling and tenderness in joints with or without.

Serum sRANKL and OPG levels in healthy donors and patients with RA at baseline and after MTX and low-dose prednisolone treatment. Serum sRANKL and OPG.

Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Ultrasound examination and conventional radiography of the second proximal interphalangeal joint at baseline (2009) and follow-up (2013). Ultrasound examination.

Patient disposition after 2 years of treatment.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Satisfaction with control of RA

Schematic depiction of categories of inflammation in 350 small joints during progression from clinically suspect arthralgiato inflammatory arthritis. Schematic.

Mean profiles over 1 year from the observed Disease Activity Score 28 (DAS28) data for the methotrexate (MTX)-exposed patients after stratifying by predicted.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Time to cessation of rectal bleeding in patients with frank bleeding at baseline. Time to cessation of rectal bleeding in patients with frank bleeding.

Sera metabolite profiles of patients with RA discriminate rituximab responders and non-responders. Sera metabolite profiles of patients with RA discriminate.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

(A) Mean NMR spectra of patient sera show differences in metabolite intensities between responders and non-responders before (a) and 6 months after (b)

Joint pain location and severity.

Kaplan-Meier estimate of drug continuation until discontinuation for tocilizumab, canakinumab, anakinra and etanercept, as a first biological agent for.

Nail photographs and MRI scans of a patient with psoriatic arthritis.

Forest plot showing the results of the meta-analysis on the effect of strength exercise on M.quadriceps femoris in people with rheumatoid arthritis and.

Forest plot showing the results of the meta-analysis on the effect of aerobic exercise on measured on VO2max in people with rheumatoid arthritis, spondyloarthritis.

Depiction of bone marrow oedema using different techniques

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

Multivariate Cox proportional hazards model of time to first serious infectious events. Multivariate Cox proportional hazards model of time to first serious.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. The final ultrasound inflammation score (USRA9) for rheumatoid arthritis. (Included.

Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.

Kaplan-Meier survival curves by severity of exacerbations in patients with COPD: (1) no acute exacerbations of COPD; (2) patients with acute exacerbations.

Presentation transcript:

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade 2 at any of 26 joints, or (B) GS= grade 3 at MTPs 1–5 or ≥ grade 2 at any other joint, (C) the need for methotrexate according to the number of joints with significant synovitis defined by GS≥ grade 2 at any of 26 joints. Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade 2 at any of 26 joints, or (B) GS= grade 3 at MTPs 1–5 or ≥ grade 2 at any other joint, (C) the need for methotrexate according to the number of joints with significant synovitis defined by GS≥ grade 2 at any of 26 joints. The number of patients per group at baseline is denoted by n. GS, grey scale; MTP, metatarsophalangeal; RA, rheumatoid arthritis. Sarah C Horton et al. RMD Open 2017;3:e000394 Copyright © BMJ Publishing Group & EULAR. All rights reserved.